Clara Grazia Chisari Selected Research

Multiple Sclerosis

11/2023	Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis.
3/2023	REal-World effectIveNess of claDribine for patients with multiple sclerosis: a Sicilian multicentric experience (REWIND study).
1/2023	A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols.
1/2023	Palliative care in multiple sclerosis.
9/2022	Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.
2/2022	Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature.
1/2022	Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies.
1/2022	Rituximab for the treatment of multiple sclerosis: a review.
1/2022	A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
1/2021	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Clara Grazia Chisari Research Topics

Disease

14	Multiple Sclerosis 11/2023 - 01/2020
6	Relapsing-Remitting Multiple Sclerosis 03/2023 - 10/2019
3	Parkinson Disease (Parkinson's Disease) 03/2024 - 01/2020
2	Progressive Multifocal Leukoencephalopathy 01/2022 - 01/2020
2	Opportunistic Infections (Opportunistic Infection) 01/2022 - 01/2020
1	Essential Tremor (Essential Tremors) 03/2024
1	Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) 01/2024
1	Weight Gain 09/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Learning Disabilities (Learning Disability) 01/2021
1	Alcoholism (Alcohol Abuse) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Craniocerebral Trauma (Head Injury) 01/2021
1	Substance-Related Disorders (Drug Abuse) 01/2021
1	Sudden Infant Death (SID) 12/2020
1	Disease Progression 01/2020
1	Optic Neuritis (Retrobulbar Neuritis) 11/2019
1	Demyelinating Diseases (Demyelinating Disease) 01/2019

Drug/Important Bio-Agent (IBA)

6	Retinaldehyde (Retinal)IBA 03/2024 - 10/2019
4	Natalizumab (Tysabri)FDA Link 09/2022 - 01/2020
4	nitazoxanide (NTZ)FDA Link 09/2022 - 01/2020
3	nabiximols (Sativex)IBA 01/2023 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 11/2023 - 01/2020
2	Rituximab (Mabthera)FDA Link 01/2022 - 01/2019
2	SteroidsIBA 09/2021 - 01/2020
2	CannabidiolIBA 10/2020 - 01/2020
2	Dronabinol (THC)FDA LinkGeneric 10/2020 - 01/2020
1	Cladribine FDA LinkGeneric 03/2023
1	TabletsIBA 03/2023
1	AdipokinesIBA 09/2021
1	Hormones (Hormone)IBA 09/2021
1	RetinoidsIBA 09/2021
1	CytokinesIBA 09/2021
1	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2021
1	Oligoclonal BandsIBA 10/2019
1	Monoclonal AntibodiesIBA 01/2019

Therapy/Procedure

6	Therapeutics 01/2022 - 01/2020
1	Palliative Care (Palliative Therapy) 01/2023
1	Hematopoietic Stem Cell Transplantation 02/2022